Use of Letermovir for Salvage Therapy for Resistant Cytomegalovirus in a Pediatric Hematopoietic Stem Cell Transplant Recipient.
Journal Article (Journal Article)
We present here the first published use of letermovir for the treatment of resistant cytomegalovirus (CMV) in a pediatric patient. A 14-year-old girl underwent a double unrelated umbilical cord blood transplantation to treat her sickle cell disease (hemoglobin SS) and developed ganciclovir-resistant CMV DNAemia with end-organ involvement that was treated successfully with a combination of foscarnet and letermovir. After she was transitioned to letermovir monotherapy for secondary prophylaxis, she developed recurrent DNAemia with laboratory-confirmed ganciclovir, foscarnet, and letermovir resistance.
Full Text
- Published version (via Digital Object Identifier)
- Pubmed Central version
- Open Access Copy from Duke
- Link to Item
Duke Authors
Cited Authors
- Kilgore, JT; Becken, B; Varga, MG; Parikh, S; Prasad, V; Lugo, D; Chang, Y-C
Published Date
- September 17, 2020
Published In
Volume / Issue
- 9 / 4
Start / End Page
- 486 - 489
PubMed ID
- 31362308
Pubmed Central ID
- PMC7495908
Electronic International Standard Serial Number (EISSN)
- 2048-7207
Digital Object Identifier (DOI)
- 10.1093/jpids/piz050
Language
- eng
Conference Location
- England